UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of September 2023
Commission File Number: 001-37353
SCINAI IMMUNOTHERAPEUTICS LTD.
(Translation of registrant’s name into English)
Jerusalem BioPark, 2nd Floor
Hadassah Ein Kerem Campus
Jerusalem, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On September 19, 2023, Scinai Immunotherapeutics Ltd. issued a press release announcing closing of $1.33 Million Registered Direct Offering.
Exhibit Index
Exhibit No. | Description | |
99.1 | Press Release dated September 19, 2023, “Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering” |
This Report on Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-239344 and 333- 271293), Form F-1 (File No. 333-267648) and Form F-3 (File No. 333- 274078), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Scinai Immunotherapeutics Ltd. | ||
Date: September 20, 2023 | By: | /s/ Amir Reichman |
Amir Reichman | ||
Chief Executive Officer |
2